文献速递糖尿病甲状腺疾病

甲状腺激素受体β激动剂在NAFLD治疗中的可能性与挑战

Thyroid Hormone Receptor-β Agonists in NAFLD Therapy: Possibilities and Challenges.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

非酒精性脂肪性肝病(NAFLD)是一种进行性代谢性肝病,发病机制不明且尚无FDA批准药物。甲状腺激素受体β(TRβ)特异性激动剂可避免甲状腺素的心脏副作用,在动物模型中显示治疗NAFLD的积极效果并已进入临床试验。本文综述TRβ特异性激动剂的研究进展并探讨其未来治疗潜力。

要点

  • 甲状腺功能减退是NAFLD的危险因素,甲状腺素可减少实验诱导NAFLD小鼠模型的肝脏脂肪。
  • TRβ主要表达于肝脏并参与肝功能,TRα主要表达于心脏并负责甲状腺素的心脏功能。
  • 使用TRβ特异性激动剂治疗NAFLD可预防心脏及其他不良副作用,多种激动剂已在动物模型显示积极疗效并进入临床试验。

核心结论

  • TRβ特异性激动剂在NAFLD动物模型中显示积极治疗效果并已进入临床试验,本综述提供其全面更新参考并探讨未来治疗潜力。

研究设计与样本

  • 综述,检索范围未在摘要中报告。

主要发现

  • 甲状腺功能减退已被确定为NAFLD的危险因素,因成人需要甲状腺素调节代谢。
  • 甲状腺素已被证明可减少实验诱导NAFLD小鼠模型的肝脏脂肪。
  • 合成甲状腺素已被证明可增加脂质代谢导致体重减轻,但甲状腺素也已被证明引起许多副作用,尤其是心脏方面。
  • TRα主要表达于心脏并负责甲状腺素的心脏功能,TRβ主要表达于肝脏并参与肝功能。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nonalcoholic fatty liver disease (NAFLD) is a progressive metabolic liver disease with an unknown pathogenesis and no FDA-approved drug treatment to date. Hypothyroidism has been identified as a risk factor for NAFLD as thyroxine is required for regulating metabolism in adults. Thyroxine has been shown to reduce fat in the livers of murine models with experimentally induced NAFLD. The use of synthetic thyroxine has been shown to increase lipid metabolism leading to weight loss; however, thyroxine has also been shown to cause many side effects, especially in the heart. Overcoming these cardiac side effects involves designing agonists specific to one of the 2 gene subtypes for the thyroid hormone (TH) receptor (TR), TRβ. While the other TH receptor subtype, TRα, is mainly expressed in the heart and is responsible for thyroxine's cardiac function, TRβ is mainly expressed in the liver and is involved in liver function. Using TRβ-specific agonists to treat NAFLD can prevent cardiac and other adverse side effects. Several TRβ-specific agonists have shown positive therapeutic effects in NAFLD animal models and have entered clinical trials. We seek to provide a comprehensive updated reference of TRβ-specific agonists in this review and explore the future therapeutic potential of TRβ-specific activation in the treatment of NAFLD.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Li L, Song Y, Shi Y, et al. Thyroid Hormone Receptor-β Agonists in NAFLD Therapy: Possibilities and Challenges. J Clin Endocrinol Metab. 2023. PMID: 36746649. doi:10.1210/clinem/dgad072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。